These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 17702653

  • 1. A vaccine against Helicobacter pylori: towards understanding the mechanism of protection.
    Aebischer T, Walduck A, Schroeder J, Wehrens A, Chijioke O, Schreiber S, Meyer TF.
    Int J Med Microbiol; 2008 Jan; 298(1-2):161-8. PubMed ID: 17702653
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Experimental model of Helicobacter pylori infection.
    Del Giudice G, Ghiara P, Rappuoli R.
    Ital J Gastroenterol Hepatol; 1998 Oct; 30 Suppl 3():S261-3. PubMed ID: 10077750
    [Abstract] [Full Text] [Related]

  • 5. Towards the development of vaccines against Helicobacter pylori: status and issues.
    Del Giudice G.
    Curr Opin Investig Drugs; 2001 Jan; 2(1):40-4. PubMed ID: 11527009
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of a vaccine against Helicobacter pylori infection.
    Michetti P.
    Ital J Gastroenterol Hepatol; 1998 Oct; 30 Suppl 3():S339-41. PubMed ID: 10077770
    [Abstract] [Full Text] [Related]

  • 8. Inflammation, immunity, and vaccines for Helicobacter pylori.
    D'Elios MM, Andersen LP.
    Helicobacter; 2009 Sep; 14 Suppl 1():21-8. PubMed ID: 19712164
    [Abstract] [Full Text] [Related]

  • 9. Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice.
    Flach CF, Mozer M, Sundquist M, Holmgren J, Raghavan S.
    Vaccine; 2012 Feb 21; 30(9):1636-43. PubMed ID: 22230589
    [Abstract] [Full Text] [Related]

  • 10. The current status of Helicobacter pylori vaccines: a review.
    Kabir S.
    Helicobacter; 2007 Apr 21; 12(2):89-102. PubMed ID: 17309745
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy.
    Blanchard TG, Eisenberg JC, Matsumoto Y.
    Vaccine; 2004 Feb 17; 22(7):888-97. PubMed ID: 15040942
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model.
    Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saiji E, Bouzourene H, Michetti P.
    Gastroenterology; 2009 Jun 17; 136(7):2237-2246.e1. PubMed ID: 19272385
    [Abstract] [Full Text] [Related]

  • 15. Progress in vaccine development against Helicobacter pylori.
    Svennerholm AM, Lundgren A.
    FEMS Immunol Med Microbiol; 2007 Jul 17; 50(2):146-56. PubMed ID: 17442014
    [Abstract] [Full Text] [Related]

  • 16. Helicobacter pylori inflammation, immunity, and vaccines.
    D'Elios MM, Andersen LP.
    Helicobacter; 2007 Oct 17; 12 Suppl 1():15-9. PubMed ID: 17727455
    [Abstract] [Full Text] [Related]

  • 17. [-Development of a mouse model for Helicobacter pylori infection in the human--progress toward vaccination against ulcer disease?-].
    Gallwitz B, Schmidt WE.
    Z Gastroenterol; 1996 Mar 17; 34(3):202-4. PubMed ID: 8650975
    [No Abstract] [Full Text] [Related]

  • 18. Systemic immunization with unadjuvanted whole Helicobacter pylori protects mice against heterologous challenge.
    Harbour SN, Every AL, Edwards S, Sutton P.
    Helicobacter; 2008 Dec 17; 13(6):494-9. PubMed ID: 19166414
    [Abstract] [Full Text] [Related]

  • 19. [Current progress in the development of prophylactic and therapeutic vaccination against H. pylori infection].
    Nishizono A.
    Nihon Rinsho; 2002 Feb 17; 60 Suppl 2():745-50. PubMed ID: 11979882
    [No Abstract] [Full Text] [Related]

  • 20. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA, Stensson A, Schön K, Lycke N.
    Scand J Immunol; 2006 Feb 17; 63(2):97-105. PubMed ID: 16476008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.